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Protective Effect of Heme Oxygenase-1 (HO-1) on the Ischemic Reperfusion Kidney 
Yuji Ishida (Department of Nephrology, Saitama Medical School, Moroyama, Iruma-gun, Saitama 350-0436, Japan)
The contribution of heme oxygenase-1 (HO-1) in ischemic renal injury is little known. To investigate 
the role of HO-1 in the kidney, we examined the role of HO-1 in the ischemic re-perfusion kidney and its 
functional significance of an induction of HO-1. 36 Wistar Kyoto rats (WKY) were divided into three groups 
as follows; group I: control group (c, n＝12), group II: Fe-protoporphyrin treated group (hemin, 40μg /kg, 
n＝12) which provided substrate for HO-1 and group III: tin-protoporphyrin treated group (Sn-PP, 40μg /kg, 
n＝12) which blocked HO-1 synthasis. Bilateral ischemic acute renal injury was produced in 36 WKY, using 
a micro bulldog clamp. Re-perfusion was started after thir ty minutes occlusion. Blood was collected for 
measurements of creatinine (Cr), blood urea nitrogen (BUN), arginine vasopressin (AVP) and the components 
of the renin-angiotensin system ; angiotensin I (Ang I), angiotensin II (Ang II), plasma renin activity (PRA), 
plasma aldosterone concentration (PAC). Urine volume and urinary excretion of sodium were measured. 
In addition, both glomerular filtration rate (GFR) and renal plasma flow (RPF) were measured using inulin 
clearance and para-amino hippurate carried out.  The kidney was removed before occlusion and at 3, 6 and 24 
hours after re-perfusion for staining of  HO-1 and aquqporin-2 (AQP-2) with immunohistochemistry method 
and measurements of mRNA levels of HO-1, endothelial constitutive nitric oxide synthase (ecNOS), and AQP-2 
with reverse-transcription polymerase chain reaction (RT-PCR). At 3 hours after re-perfusion, HO-1 activity was 
increased significantly and most pronounced in the tubules in the kidney. In Sn-PP, both GFR and RPF group were 
significantly decreased and the suppression of the expression of HO-1 mRNA was observed. On the contrary, 
hemin treatment induced a significant elevation of GFR and RPF and increases in the expression of HO-1. After 
24 hours in Sn-PP treated group, the expression of AQP-2 was suppressed accompanied with the increase of urine 
volume. HO-1 plays a key role in RPF and GFR in re-perfusion kidney and moreover is linked to regulate the 
expression of AQP-2. From these data, we conclude that the induction of heme oxygenase is a protective response 
in re-perfusion kidney after renal ischemia. 
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にPE-10カテーテル（Clay Adams Co., U.S.A.）を挿入，
血圧，心拍数を連続モニターした．大腿静脈内には





















constitutive nitric oxide synthase（ecNOS）mRNAの











に右内頚静脈にPE-10カテーテル（Clay Adams Co., 
U.S.A.），輸液用に左鼠経静脈内にPE-50カテーテル
（Clay Adams Co., U.S.A.）を挿入し，持続注入ポンプ








理食塩水ならびに1％ bovine serum albumin（BSA），
1％濃度の5 - sec - butyl - 5 - ethyl - 2 - thiobarbituric acid



























体液として， 抗Ang I，抗Ang II および抗aldosterone
抗体ウサギ血清を，第 2抗体液として，抗ウサギ
抗体ヤギ血清を用い，そして，トレーサー溶液と













氷点降下法を用いた浸透圧計（Model 3MO, Advanced 











































LabのABC Kit（VEC:2001）でそれぞれ（200μl  Avidin 






























































処理を行う．DNase I 10×Buffer，DNase I amplification 
Grade（GIBCO BRL），template / total 10μl を37℃ 15
分インキュベーションし， DNase I処理を行い，それに，
EDTA1μl 加え70℃，15分間インキュベーションし，
DNase I の反応を停止した．これにOligo （dT） primer
（GIBCO BRL）3μl，5× first Buffer 6μl，DTT 3μl，dNTP 
mixture（TAKARA） 6μl，Super script II（GIBCO BRL） 
0.7μlを加え，42℃，60分インキュベーションし，RT
反応をさせる．DEPC水32.5μl，DMSO 5μl，10×PCR 
Buffer 5μl，dNTP mixture 4μl，Primer Fw 1μl，Rv 1μl，
template （cDNA） 1μl，rTaq polymerase（TAKARA） 0.5μl 











はOne-way analysis of variance（ANOVA）を用いた後，





























































1.22± 0.44 ng/ml/hrから 2.14± 0.46 ng/ml/hr，


















Fig. 1.(a) Changes in systemic blood pressure after 
re-perfusion of bilateral kidney in WKY. (■)control group; 
(● )hemin group; and (▲ ) Sn-PP group. (b) Changes in 
urine volume after re-perfusion of bilateral kidney in WKY. 
Open column shows control group; dot column shows hemin 
group; and closed column shows Sn-PP group.(c)Changes 
in urinary excretion of sodium after re-perfusion of bilateral 
kidney in WKY.; open column shows control group; dot 
column shows hemin group; and closed column shows Sn-PP 
group.Values are expressed as the means±SEM in each 
group. Statistically significant difference compared with pre 
treatment value in each group.＋＋P＜0.01, ＋P＜0.05,vs.pre 
treatment value. Statistically significant difference compared 
with control group at identical times. **P＜0.01, *P＜0.05 



































Fig. 2. Changes in (a) serum creatinine, (b) blood urea 
nitrogen (BUN), (c) serum sodium (Na), and (d) serum 
potassium (K) after re-perfusion of bilateral kidney in WKY. 
Open column shows control group; dot column shows hemin 
group; and closed column shows Sn-PP group.Values are 
expressed as the means±SEM in each group.Statistically 
significant dif ference compared with pre treatment value 
in each group. ＋＋P＜0.01, ＋P＜0.05 vs. pre treatment value. 
Statistically significant dif ference compared with control 
group at identical times. *P＜0.05, vs. control group.
Fig. 3. (a) Changes in plasma renin activity (PRA), (b) 
plasma aldosterone concentration (PAC), and (c) arginine 
vasopressin (AVP) after re-perfusion of bilateral kidney in 
WKY. Open column shows control group; dot column shows 
hemin group; and closed column shows Sn-PP group. Values 
are expressed as the means±SEM in each group.Statistically 
significant difference compared with pre treatment value in 
each group. ＋P＜0.05 vs. pre treatment value.
Fig. 4. Immunohistochemistr y of Heme oxygenase-1 in 
kidney(a) HO-1 was expressed in tubules after 3hours after 
ischemia re-perfusion kidney (control), (b) in tubules at 
3 hours after ischemia re-per fusion kidney treated with 
hemin (hemin), and (c) in tubules at 3 hours after ischemia 



















Fig. 6. Expression of ecNOS mRNA in the kidney. Lane 
1 shows pre ischemia, lane 2 at 3 hrs after re-per fusion 
(control), lane 3 at 3 hrs after re-per fusion treated with 
hemin (hemin), lane 4 at 3 hrs after re-perfusion treated with 
Sn-PP (Sn-PP) and lane 5 at 6 hrs after re-perfusion kidney 
(control). Expressions of ecNOS mRNA was analyzed by 
semi-quantitative RT-PCR, as described in method. Values are 
mean ± SEM percentage changes in expression of mRNA 
(n＝ 4).
Fig. 5.  Express ion o f  HO-1  mRNA in  the  k idney.  
Lane 1 shows pre ischemia, lane 2 at 3 hrs after re-perfusion 
(control), lane 3 at 3 hrs after re-per fusion treated with 
hemin (hemin), lane 4 at 3 hrs after re-perfusion treated with 
Sn-PP (Sn-PP) and lane 5 at 6 hrs after re-perfusion kidney 
(control). Expressions of HO-1 mRNA was analyzed by 
semi-quantitative RT-PCR, as described in method. Values 
are mean±SEM percentage changes in expression of mRNA 
(n＝4). ＋＋P＜0.01 vs. pre ischemia re-perfusion rats. **P















Fig. 7. Immunohistochemistry of Aquaporin-2 in kidney.(a) AQP-2 was expressed in pre ischemia kidney, (b) Figure shows the 
expression of AQP-2 in tubules 24 hours after ischemia re-perfusion kidney in control rats (control), (c) in tubules 24 hours after 
ischemia re-perfusion kidney in hemin treated rats (hemin), and (d) in tubules in 24 hours after ischemia re-perfusion kidney in 
























































Fig. 8. Expression of AQP-2 mRNA in the kidney. Lane 
1 shows pre ischemia, lane 2 at 3 hrs after re-per fusion 
(control), lane 3 at 3 hrs after re-per fusion treated with 
hemin (hemin), lane 4 at 3 hrs after re-perfusion treated with 
Sn-PP (Sn-PP) and lane 5 at 6 hrs after re-perfusion kidney 
(control).Expressions of AQP-2 mRNA was analyzed by 
semi-quantitative RT-PCR, as described in Method. Values 
are mean±SEM percentage changes in expression of mRNA 
(n＝4). 
Fig.  9.  (a)  Changes  in  g lomer ular  fi  l t ra t ion  ra te  
( G F R ) ,  ( b )  r e n a l  p l a s m a  fl  o w  ( R P F ) ,  ( c )  u r i n e  
osmolality(mOsm/kg.H2O), and (d) cGMP after re-perfusion 
of bilateral kidney in WKY. Open column shows control 
group; dot column shows hemin group; and closed column 
shows Sn-PP group. Values are expressed as the means
±SEM in each group. Statistically signifi cant dif ference 
compared with control group at identical times. **P＜0.01, 
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